SEC Form 4 · accession 0001209191-18-041386
HERON THERAPEUTICS, INC. /DE/ · HRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kimberly Manhard
Officer — Executive VP, Drug Development
Period of report
Jul 2, 2018
Accepted (ET)
Jul 3, 2018 · 9:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818033
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 2, 2018 | M | 6,000 | $13.00 | A | 6,000 | D | |
| Common StockF2 | Jul 2, 2018 | S | 5,900 | $37.5074 | D | 100 | D | |
| Common Stock | Jul 2, 2018 | S | 100 | $38.85 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $13.00 | Jul 2, 2018 | M | 6,000 | D | — | Dec 21, 2026 | Common Stock | 6,000 | 88,416 | D |
Explanation of responses
- F1The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 23, 2018.
- F2The range of sales prices received was $37.70 to $38.60. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F3The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (12/21/2016).